Logo Image
Opinion|Videos|May 12, 2025

Choosing Wisely: Insights from an MAIC and eXalt3

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).

Episodes in this series

Comparative Data Analysis and Ensartinib Approval

Key Themes:

  • Matching-adjusted indirect comparisons (MAIC) of lorlatinib versus alectinib or brigatinib
  • Overview of the eXalt3 study for ensartinib
  • Implications of ensartinib’s December 2024 FDA approval

Notable Insights:

  • Dr Dietrich analyzed insights from the MAIC of lorlatinib versus other ALK inhibitors

Dr Lovly provided an overview of the eXalt3 study following ensartinib’s recent FDA approval in December 2024

Related Content